Integral University 2009 M.Tech Biotechnology Immunotechnology - Question Paper
Roll No.
THIRD SEMESTER-EXAMINATION,'2009-10 IMM UNOTECHNO LOGY
Total Marks : 100
Note : (i) Attempt any FIVE questions.
(ii) "Marks are indicated against each question.
1. (a) Comment on the role of cytokines which play a role in B cell activation during the production of antibodies. Name the primary and secondary mediators of inflammation. Which cytokines are secreted by activated human mast cells? 15
(b) Comment on the therapeutic potential of interferons. ' 5
2. (a) How does the dose and route of administration of antigens affect
the immune response of he human body? Give methodological details of purification of antibodies from blood employing an immunoadsorbant. 15
(b) What are the disadvantages of use of polyclonal antibodies? 5
3. (a) Give an account of the production of the following : 10
(i) Chimeric monoclonal antibody '(Ii)' Humanized monoclonal antibody
(b) Give the flow chart of the production of monoclonal antibodies by hybridoma technology. Give three practical uses of monoclonal antibodies. 10
P.T.O.
1
jive an account of the mechanisms adopted by HIV to evade the urveiliance of the host immune system. How does the virus -ause the immune suppression in the hosi? What is HAART nerapy? 10
'omment in brief ' about the uses of live attenuated nicroorsanisms, toxoids and killed microorganisms in vaccine preparation. What are DNA vaccines? 10
vVrite notes on the following: . 15
(i) Allograft (ii) Isograft
(iii) Xenograft (iv) HLA typing
(v) Generalized immune suppression
Which test should be performed in the donor and recipients prior
;o kTdney transplantation to ensure successful
transplantation? 5
t
Draw a labeled diagram of HIV virus showing its components. Wnat is the significance of gag, 'pol' and 'env' sequences of the HIV genome? 15
Explain the mechanism of evasion of immune response by tumors. 5
short notes on any Four of the following : 0 5 x 4 = 20
. 9 '
interferons
Immunotheraov for asthma
I
immi inodiaonosis of infectious agents
|
Attachment: |
| Earning: Approval pending. |
